A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/00 (2006.01) A61K 35/12 (2006.01) A61K 38/19 (2006.01) A61K 38/20 (2006.01) C07K 14/55 (2006.01) C12N 15/85 (2006.01) A61K 48/00 (2006.01)
Patent
CA 2121127
2121127 9307906 PCTABS00021 A novel method of tumor immunotherapy is described comprising the genetic modification of cells resulting in the secretion of cytokine gene products to stimulate a patient's immune response to tumor antigens. In one embodiment, autologous fibroblasts genetically modified to secrete at least one cytokine gene product are utilized to immunize the patient in a formulation with tumor antigens at a site other than an active tumor site. In another embodiment, cells genetically modified to express at least one tumor antigen product and to secrete at least one cytokine gene product are utilized in a formulation to immunize the patient at a site other than an active tumor site.
Fakhrai Habib
Friedman Theodore
Gage Fred H.
Royston Ivor
Sobol Robert E.
Gowling Lafleur Henderson Llp
San Diego Regional Cancer Center
LandOfFree
Lymphokine gene therapy of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lymphokine gene therapy of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lymphokine gene therapy of cancer will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1954731